Table 1 The baseline information of major trials
From: Effect of renal denervation on long-term outcomes in patients with resistant hypertension
Trials | Country | Patients | Study design | Indicators | Follow-up (months) |
|---|---|---|---|---|---|
EnligHTN I | Australia | 46 | First-in-human, prospective, multi-centre, non-randomized study | OBP and ABPM | 12 |
EnligHTN III | Australia and New Zealand | 39 | First-in-human, prospective, multi-center, non-randomized study | OBP and ABPM | 12, 24 |
Global SYMPLICITY Registry | Canada, Western Europe, Latin America, Eastern Europe, South Africa, Middle East, Asia, Australia, and New Zealand | 2237 | Prospective, open-label, single-arm, observational registry | OBP and ABPM | 12, 24, 36 |
Krum | Australian and European | 45 | Single-arm | OBP | 12 |
RAPID | Europe and New Zealand | 50 | Prospective, multicentre, single-arm study | OBP and ABPM | 12 |
REDUCE-HTN | Germany | 146 | Prospective, multicentre, single-arm study | OBP and ABPM | 12, 24 |
Symplicity HTN-1 | Australia, Europe, and USA | 153 | Single-arm | OBP | 12, 24, 36 |
Symplicity HTN-2 | Australia | 106 | Randomized controlled crossovertrial | OBP | 12, 36 |
Symplicity HTN-3 | United States | 535 | Prospective, single-blind, crossover, randomized, sham-controlled trial | OBP and ABPM | 12 |